review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | R A Braithwaite | |
R P Archer | |||
L A King | |||
A T Kicman | |||
P D Sainsbury | |||
P2860 | cites work | Fatal poisoning with a new phenylethylamine: 4-methylthioamphetamine (4-MTA) | Q28139597 |
Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine | Q28256742 | ||
5-iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine | Q28268394 | ||
Bioanalysis of new designer drugs | Q33748885 | ||
Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). | Q33996413 | ||
2-Aminoindans of pharmacological interest | Q34218400 | ||
Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential | Q34461106 | ||
[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues | Q34549018 | ||
Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs | Q34645841 | ||
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). | Q34997151 | ||
Reinforcing effects of certain serotonin-releasing amphetamine derivatives. | Q52203594 | ||
Commentary on Halpern et al. (2011): strengthening the case against functionally significant serotonergic neurotoxicity in human MDMA (ecstasy) users. | Q52298270 | ||
Cat and mouse: the analytical toxicology of designer drugs | Q83409031 | ||
P433 | issue | 7-8 | |
P304 | page(s) | 479-482 | |
P577 | publication date | 2011-07-11 | |
P1433 | published in | Drug Testing and Analysis | Q3040088 |
P1476 | title | Aminoindanes--the next wave of 'legal highs'? | |
P478 | volume | 3 |
Q48625700 | A brief history of 'new psychoactive substances'. |
Q47869636 | Amide-Directed C-H Sodiation by a Sodium Hydride/Iodide Composite. |
Q38510888 | An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). |
Q83354105 | Annual banned-substance review: analytical approaches in human sports drug testing |
Q37663461 | Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals |
Q28255977 | Impact of the emergence of designer drugs upon sports doping testing |
Q42395888 | Locomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents |
Q38123776 | MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') toxicity: a brief overview and update |
Q38191529 | New phenethylamines in Europe |
Q91020544 | The metabolic fate of two new psychoactive substances - 2-aminoindane and N-methyl-2-aminoindane - studied in vitro and in vivo to support drug testing |
Q97887124 | Understanding the Contribution of Individual Amino Acid Residues in the Binding of Psychoactive Substances to Monoamine Transporters |